Maraviroc acts as:: (A) Reverse transcriptase inhibitor, (B) Protease inhibitor, (C) Entry inhibitor, (D) None of the above
Answer is C. Maraviroc binds specifically and selectively to CCR5, one of two coreceptors necessary for entrance of HIV into CD4+ cells, thus blocking entry of CCR5-tropic HIV into these cells. Ref: Katzung 11th edition Chapter 49.